The interferon-inducible protein tetherin inhibits hepatitis B virus virion secretion

Journal of Virology

Volumn 89, Issue 18, 2015, Pages 9200-9212

  Yan, Ran ^a   Zhao, Xuesen ^b   Cai, Dawei ^a   Liu, Yuanjie ^a   Block, Timothy M ^b   Guo, Ju Tao ^b   Guo, Haitao ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA REPLICATION; ENDOPLASMIC RETICULUM; GENETIC TRANSCRIPTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPRECIPITATION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; TRANSMISSION ELECTRON MICROSCOPY; VIRION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; ULTRASTRUCTURE; VIROLOGY; VIRUS CAPSID; VIRUS RELEASE;

ANTIGENS, CD; ANTIVIRAL AGENTS; CAPSID; CELL LINE; GENE EXPRESSION REGULATION; GLYCOSYLPHOSPHATIDYLINOSITOLS; GPI-LINKED PROTEINS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; VIRUS RELEASE; VIRUS REPLICATION;

EID: 84940515778     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00933-15     Document Type: Article

References (71)

1. Liang TJ. 2009. Hepatitis B: the virus and disease. Hepatology 49:S13-S21. http://dx.doi.org/10.1002/hep.22881.
2. Block TM, Guo H, Guo JT. 2007. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 11:685-706, vii. http://dx.doi.org/10.1016/j.cld.2007.08.002.
3. Deny P, Zoulim F. 2010. Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris) 58:245-253. http://dx.doi.org/10.1016/j.patbio.2010.05.002.
4. Trepo C, Chan HL, Lok A. 2014. Hepatitis B virus infection. Lancet 384:2053-2063. http://dx.doi.org/10.1016/S0140-6736(14)60220-8.
5. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbiol Mol Biol Rev 64:51-68. http://dx.doi.org/10.1128/MMBR.64.1.51-68.2000.
6. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070-1083. http://dx.doi.org/10.1053/j.gastro.2013.12.024.
7. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049. http://dx.doi.org/10.7554/eLife.00049.
8. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. 2012. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol 86:9443-9453. http://dx.doi.org/10.1128/JVI.00873-12.
9. Guo H, Mao R, Block TM, Guo JT. 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol 84:387-396. http://dx.doi.org/10.1128/JVI.01921-09.
10. Patient R, Hourioux C, Roingeard P. 2009. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 11:1561-1570. http://dx.doi.org/10.1111/j.1462-5822.2009.01363.x.
11. Prange R. 2012. Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol 201:449-461. http://dx.doi.org/10.1007/s00430-012-0267-9.
12. Cai X, Chiu YH, Chen ZJ. 2014. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 54:289-296. http://dx.doi.org/10.1016/j.molcel.2014.03.040.
13. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat Immunol 7:131-137. http://dx.doi.org/10.1038/ni1303.
14. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559-568. http://dx.doi.org/10.1038/nri2314.
15. Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits hepatitis B andCvirus replication. J Virol 79:3851-3854. http://dx.doi.org/10.1128/JVI.79.6.3851-3854.2005.
16. Isogawa M, Robek MD, Furuichi Y, Chisari FV. 2005. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79:7269-7272. http://dx.doi.org/10.1128/JVI.79.11.7269-7272.2005.
17. Wieland SF, Chisari FV. 2005. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79:9369-9380. http://dx.doi.org/10.1128/JVI.79.15.9369-9380.2005.
18. Wang H, Ryu WS. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6:e1000986. http://dx.doi.org/10.1371/journal.ppat.1000986.
19. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. 2011. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol 55:762-769. http://dx.doi.org/10.1016/j.jhep.2010.12.042.
20. Liu Y, Li J, Chen J, Li Y, Wang W, Du X, Song W, Zhang W, Lin L, Yuan Z. 2015. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol 89:2287-2300. http://dx.doi.org/10.1128/JVI.02760-14.
21. Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H. 2011. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 85:1048-1057. http://dx.doi.org/10.1128/JVI.01998-10.
22. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83:847-858. http://dx.doi.org/10.1128/JVI.02008-08.
23. Guo F, Han Y, Zhao X, Wang J, Liu F, Xu C, Wei L, Jiang JD, Block TM, Guo JT, Chang J. 2015. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother 59:1273-1281. http://dx.doi.org/10.1128/AAC.04321-14.
24. Chang J, Block TM, Guo JT. 2012. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 96:405-413. http://dx.doi.org/10.1016/j.antiviral.2012.10.001.
25. Scaglione SJ, Lok AS. 2012. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142:1360-1368.e1361. http://dx.doi.org/10.1053/j.gastro.2012.01.044.
26. Chisari FV, Isogawa M, Wieland SF. 2010. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58:258-266. http://dx.doi.org/10.1016/j.patbio.2009.11.001.
27. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513-545. http://dx.doi.org/10.1146/annurev-immunol-032713-120231.
28. Uprichard SL, Wieland SF, Althage A, Chisari FV. 2003. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A 100:1310-1315. http://dx.doi.org/10.1073/pnas.252773599.
29. Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block TM, Guo JT, Guo H. 2013. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog 9:e1003494. http://dx.doi.org/10.1371/journal.ppat.1003494.
30. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. 2013. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 9:e1003613. http://dx.doi.org/10.1371/journal.ppat.1003613.
31. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. 2012. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122:529-537. http://dx.doi.org/10.1172/JCI58847.
32. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. 2005. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 102:9913-9917. http://dx.doi.org/10.1073/pnas.0504273102.
33. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 84:9332-9340. http://dx.doi.org/10.1128/JVI.00918-10.
34. Gao B, Duan Z, Xu W, Xiong S. 2009. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50:424-433. http://dx.doi.org/10.1002/hep.23011.
35. Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, Yuan Z. 2010. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 84:6387-6399. http://dx.doi.org/10.1128/JVI.00236-10.
36. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221-1228. http://dx.doi.org/10.1126/science.1243462.
37. Nguyen DH, Hu J. 2008. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 82:6852-6861. http://dx.doi.org/10.1128/JVI.00465-08.
38. Nguyen DH, Gummuluru S, Hu J. 2007. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81:4465-4472. http://dx.doi.org/10.1128/JVI.02510-06.
39. Neil SJ. 2013. The antiviral activities of tetherin. Curr Top Microbiol Immunol 371:67-104. http://dx.doi.org/10.1007/978-3-642-37765-5_3.
40. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org/10.1038/nature06553.
41. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83:1837-1844. http://dx.doi.org/10.1128/JVI.02211-08.
42. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola gly-coprotein. Proc Natl Acad Sci U S A 106:2886-2891. http://dx.doi.org/10.1073/pnas.0811014106.
43. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83:9672-9681. http://dx.doi.org/10.1128/JVI.00597-09.
44. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83:2382-2385. http://dx.doi.org/10.1128/JVI.01607-08.
45. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S. 2010. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol 84:10569-10580. http://dx.doi.org/10.1128/JVI.00103-10.
46. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84: 12646-12657. http://dx.doi.org/10.1128/JVI.01328-10.
47. Yondola MA, Fernandes F, Belicha-Villanueva A, Uccelini M, Gao Q, Carter C, Palese P. 2011. Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol 85:2480-2491. http://dx.doi.org/10.1128/JVI.02188-10.
48. Watanabe R, Leser GP, Lamb RA. 2011. Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 417:50-56. http://dx.doi.org/10.1016/j.virol.2011.05.006.
49. Mangeat B, Cavagliotti L, Lehmann M, Gers-Huber G, Kaur I, Thomas Y, Kaiser L, Piguet V. 2012. Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem 287:22015-22029. http://dx.doi.org/10.1074/jbc.M111.319996.
50. Bampi C, Rasga L, Roux L. 2013. Antagonism to human BST-2/tetherin by Sendai virus glycoproteins. J Gen Virol 94:1211-1219. http://dx.doi.org/10.1099/vir.0.051771-0.
51. Wang SM, Huang KJ, Wang CT. 2014. BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface. Virology 449:287-296. http://dx.doi.org/10.1016/j.virol.2013.11.030.
52. Amet T, Byrd D, Hu N, Sun Q, Li F, Zhao Y, Hu S, Grantham A, Yu Q. 2014. BST-2 expression inhumanhepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr Mol Med 14: 349-360. http://dx.doi.org/10.2174/1566524013666131118111719.
53. Pan XB, Qu XW, Jiang D, Zhao XL, Han JC, Wei L. 2013. BST2/tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res 98:54-60. http://dx.doi.org/10.1016/j.antiviral.2013.01.009.
54. Ye L, Wang X, Li J, Liu J, Ramirez SH, Wu J, Ho W. 2012. Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes. Innate Immun 18:398-405. http://dx.doi.org/10.1177/1753425911412984.
55. Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer-Avni Y, Taube R. 2012. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 428:98-111. http://dx.doi.org/10.1016/j.virol.2012.03.011.
56. Swiecki M, Omattage NS, Brett TJ. 2013. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor. Mol Immunol 54:132-139. http://dx.doi.org/10.1016/j.molimm.2012.11.008.
57. Venkatesh S, Bieniasz PD. 2013. Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog 9:e1003483. http://dx.doi.org/10.1371/journal.ppat.1003483.
58. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. 2007. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 81:12472-12484. http://dx.doi.org/10.1128/JVI.01123-07.
59. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41:1715-1720.
60. Guo H, Pan X, Mao R, Zhang X, Wang L, Lu X, Chang J, Guo JT, Passic S, Krebs FC, Wigdahl B, Warren TK, Retterer CJ, Bavari S, Xu X, Cuconati A, Block TM. 2011. Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother 55:478-486. http://dx.doi.org/10.1128/AAC.00989-10.
61. Ning X, Nguyen D, Mentzer L, Adams C, Lee H, Ashley R, Hafenstein S, Hu J. 2011. Secretion of genome-free hepatitis B virus-single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog 7:e1002255. http://dx.doi.org/10.1371/journal.ppat.1002255.
62. Gerlich WH, Glebe D, Schuttler CG. 2007. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 14(Suppl 1):16-21. http://dx.doi.org/10.1111/j.1365-2893.2007.00912.x.
63. Lv M, Wang J, Zhu Y, Wang X, Zuo T, Liu D, Zhang J, Wu J, Zhang H, Kong W, Yu X. 2013. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin. FEBS Lett 587:37-43. http://dx.doi.org/10.1016/j.febslet.2012.11.022.
64. Roingeard P, Sureau C. 1998. Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis. Hepatology 28:1128-1133. http://dx.doi.org/10.1002/hep.510280431.
65. Bardens A, Doring T, Stieler J, Prange R. 2011. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner. Cell Microbiol 13:602-619. http://dx.doi.org/10.1111/j.1462-5822.2010.01557.x.
66. Hoofnagle JH, Gerety RJ, Ni LY, Barker LF. 1974. Antibody to hepatitis B core antigen.Asensitive indicator of hepatitis B virus replication.NEngl J Med 290:1336-1340.
67. Hoofnagle JH, Gerety RJ, Barker LF. 1973. Antibody to hepatitis-B-virus core in man. Lancet ii:869-873.
68. Liu Y, Luo S, He S, Zhang M, Wang P, Li C, Huang W, Hu B, Griffin GE, Shattock RJ, Hu Q. 2015. Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins. Virology 475:96-109. http://dx.doi.org/10.1016/j.virol.2014.11.005.
69. Douglas JL, Gustin JK, Viswanathan K, Mansouri M, Moses AV, Fruh K. 2010. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog 6:e1000913. http://dx.doi.org/10.1371/journal.ppat.1000913.
70. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. 2007. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45: 1056-1075. http://dx.doi.org/10.1002/hep.21627.
71. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511. http://dx.doi.org/10.1016/j.cell.2009.08.039.